ClinicalTrials.gg
RecruitingNCT07354568PROMIXUpdated Jan 21, 2026

Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock

An observational study in Cardiogenic Shock Acute, Bypass, Cardiopulmonary and Septic Shock, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Centre Hospitalier Universitaire, Amiens · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens — 6 open to participants now, 7 under way, 2 of them phase 3. Shock, Septic · Centre Hospitalier Universitaire, Amiens.

Started
2025
with 3 others
Observational
6 of 11
3 open now
Registered
11th of 11
by date

Among the 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens, this one is one of 4 that started in 2025, is one of 6 observational ones, and was the 11th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

6 of the 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens, or all of them as a file.
02

Study summary

Mixed cardiogenic-vasoplegic shock (M-CS) represents a distinct and severe phenotype of cardiogenic shock characterized by concomitant myocardial dysfunction and inappropriate systemic vasodilation. Despite its clinical relevance, the epidemiology, management, and outcomes of M-CS remain poorly defined.

This retrospective, multicenter, observational registry aims to evaluate the clinical outcomes and prognostic factors associated with mixed cardiogenic-vasoplegic shock. The study will analyze clinical, biological, and invasive hemodynamic data routinely collected during patient management for M-CS.

All included patients will have been admitted for cardiogenic shock, with or without vasoplegia, defined by low cardiac output and, when present, decreased systemic vascular resistance despite adequate filling pressures requiring vasopressor support.

The primary objective is to describe mortality and organ failure rates, while secondary analyses will identify determinants of adverse outcomes and potential phenotypic subgroups.

The PROMIX registry will be conducted across three French university hospitals (CHU Amiens-Picardie, CHU Dijon-Bourgogne, and CHU Rouen-Normandie).

This study is non-interventional, involving only data obtained as part of routine critical care, and will provide the first multicenter overview of this complex and underrecognized form of cardiogenic shock.

03

Conditions studied

  • Cardiogenic Shock Acute
  • Bypass, Cardiopulmonary
  • Septic Shock
  • Mechanical Circulatory Support
  • Myocardial Infarction (MI)
  • Cardiogenic Shock Post Myocardial Infarction

Keywords

  • VA-ECMO
  • Cardiogenic Shock
  • Mechanical Circulatory Support
  • Vasopressor
  • Mixed Cardiogenic Shock
  • post cardiotomy shock
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include adult patients (>18 years old) admitted to an intensive care unit for mixed cardiogenic shock (M-CS), defined by the coexistence of low cardiac output and, when present, vasoplegia requiring vasopressor support (norepinephrine >0.15 µg/kg/min) despite adequate filling pressures. Eligible patients must meet at least SCAI stage B criteria for cardiogenic shock.

Patients with major missing data, particularly on vasopressor dosing, or those who have expressed opposition to data use will be excluded. This population represents a heterogeneous, high-risk group combining features of cardiogenic and vasoplegic circulatory failure, including ischemic, post-cardiotomy, and septic cardiomyopathy etiologies. The PROMIX study aims to better characterize clinical trajectories, hemodynamic profiles, and outcomes of these patients through clustering and phenotypic analyses.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (>18 years old)
  • Admitted to an intensive care unit for cardiogenic shock, at least SCAI stage C
  • No opposition to data use

Exclusion criteria

Exclusion Criteria:

  • Missing key data, particularly regarding vasopressor doses and outcomes.
  • Pregnant women
  • Non-eligible shock etiologies, including but not limited to:
  • Anaphylactic shock,
  • Isolated hemorrhagic shock,
  • Severe burns or major trauma,
  • Severe acute pancreatitis,
  • Fulminant hepatic failure,
  • Neurogenic shock.
  • Adult under legal protection (guardianship, curatorship, or judicial protection).
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Mixed Cardiogenic-Vasoplegia Shock

    Patients hospitalized in an intensive care unit (ICU) or cardiac ICU for cardiogenic shock, at least stage C according to the SCAI classification. Vasoplegia was defined by the requirement of norepinephrine \> 0.20 µg/kg/min (γ/kg/min) to maintain a mean arterial pressure ≥ 65 mmHg.

  • Patients with Cardiogenick Shock Without Vasoplegia

    Patients hospitalized in an intensive care unit (ICU) or cardiac ICU for cardiogenic shock, at least stage C according to the SCAI classification.

06

What researchers measure

Primary outcomes

  1. All-cause mortality at 90 days

    documented death occurring within 90 days following ICU admission

    Time frame: 90 days

Secondary outcomes

  1. Clinical characteristics and management trajectories

    This outcome is descriptive in nature and aims to characterize the study population. Baseline variables (e.g., age, sex, cardiovascular history, comorbidities, and etiology of shock) will be reported separately using appropriate units for each variable (e.g., years, proportions, or categories), without aggregation into a single summary measure.

    Time frame: 90 days

  2. Phenotyping Cardiogenic Shock by Clustering

    Identification of subgroups using unsupervised classification methods (clustering) and comparison of 90-day mortality rates.

    Time frame: 90 days

  3. Evolution of the SCAI Classification

    Dynamic Evolution of the SCAI Classification (A to E) during the ICU stay. Each stage of classification is recording each day and during all ICU stay.

    Time frame: 90 days

  4. Evolution of Arterial Pressure

    To assess the dynamic evolution of systolic, diastolic, and mean blood pressure (in mmHg) from Day 0 (D0) to Day 7 (D7)

    Time frame: 7 days

  5. Evolution of Norepinephrine Equivalent (NEE) Requirement

    NEE (expressed in µg/kg/min) will be calculated at predefined time points: D0, D1, D3, D5, and D7, using standardized conversion factors to express all vasopressor doses as norepinephrine equivalents.

    Time frame: 7 days

  6. Evolution of Vasopressor Requirement

    To assess the dynamic evolution of vasopressor and inotropic support quantified using the Vasopressor-Inotropic Score (VIS). VIS is calculated as a composite score based on standardized doses of vasopressors and inotropes, with higher scores indicating greater vasopressor and inotropic support (worse hemodynamic severity). VIS values will be assessed at predefined time points Day 0, Day 1, Day 3, Day 5, and Day 7 after shock onset.

    Time frame: 7 days

  7. Clinical outcomes

    Use of renal replacement therapy and mechanical circulatory support (VA-ECMO, Impella, intra-aortic balloon pump).

    Time frame: 90 days

  8. ICU length of stay

    Duration of ICU length of stay (days) since the ICU admission

    Time frame: 90 days

  9. Hospital lenght of stay

    Duration of the Hospital lenght of stay (days) since the hospital admission and home discharge.

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jan 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 21, 2026
StartActual
Oct 20, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07354568
Responsible party
Beyls (Doctor, Principal Investigator, Centre Hospitalier Universitaire, Amiens) — Principal investigator
First posted
Jan 21, 2026
Start date
Oct 20, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jan 21, 2026

Study contacts

Christophe Beyls, MD, PhD
Contact
beyls.christophe@chu-amiens.fr
+ 33 322087866

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion